Action to be taken when facing one or more cases of whooping-cough;Conduite à tenir devant un ou plusieurs cas de coqueluche

Archives de Pediatrie

Volumn 12, Issue 8, 2005, Pages 1281-1291

  Floret, D ^a   Bonmarin, I ^b   Deutsch, P ^c   Gaudelus, J ^d   Grimprel, E ^e   Guerin N ^f   Guiso, N ^f   Morer, I ^g  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b INSTITUT DE VEILLE SANITAIRE   (France)

^c Direction Generale de la Sante   (France)

^d HÔPITAL JEAN VERDIER   (France)

^e ARMAND TROUSSEAU HOSPITAL   (France)

^f INSTITUT PASTEUR   (France)

^g AFSSAPS   (France)

Author keywords

Macrolides; Nosocomial infection; Pertussis; Prophylaxis; Vaccination

Indexed keywords

MACROLIDE; PERTUSSIS VACCINE;

ANTIBIOTIC THERAPY; BACTERIUM CONTAMINATION; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BORDETELLA PERTUSSIS; DISEASE CLASSIFICATION; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; PERTUSSIS; POLYMERASE CHAIN REACTION; REVIEW; SERODIAGNOSIS;

EID: 22944466368     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcped.2005.01.036     Document Type: Article

References (50)

1. S. Baron, E. Grimprel, and V. Tirard-Fleury Recommandations lors de cas grouṕs de coqueluche BEH 52 1996
2. D. Antona, E. Bussìre, N. Guignon, G. Badeyan, and D. Ĺvy-Bruhl La couverture vaccinale des enfants d'âge pŕscolaire en France en 2000 Eurosurveillance 8 6 2003 139
3. Données consultables à l'URL:: http://sc8.vesinet.inserm. fr:1080/.
4. D. Floret Groupe de pathologie infectieuse ṕdiatrique, Groupe francophone de ŕanimation et urgence ṕdiatrique Les d́c̀s par infection bact́rienne communautaire. Enqûte dans les services de ŕanimation ṕdiatrique fraņais Arch. Pediatr. 8 suppl 4 2001 705 711
5. D. Güris Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996 CID 28 1999 1230 1237
6. S. Baron, P. B́gú, and J.C. Desenclos Évaluation ́pid́miologique, clinique et microbiologique de la coqueluche en France 1993-1994 BEH 19 1995 83 85
7. Renacoq®: Surveillance de la coqueluche à l'hôpital en 2000. Surveillance nationale des maladies infectieuses:: 1998-2000. Données consultables à l'URL:http://www.invs.sante.fr/ publications/default.htm.
8. Renacoq®: Surveillance de la coqueluche ̀ l'hôpital en 2001 BEH 44 2003
9. C.H. Wirsing von Konig, S. Halperin, M. Riffelmann, and N. Guiso Pertussis of adults and infants Lancet Infect. Dis. 2 2002 744 750
10. J.D. Nelson The changing epidemiology of pertussis in young infants. The role of adults as reservoir of infection Am. J. Dis. Child. 13 2 1978 371 373
11. C.H. Wirsing von Konig, S. Postels-Multani, H.L. Bock, and H.J. Schmitt Pertussis in adults: frequency of transmission after household exposure Lancet 346 1995 1326 1329
12. S. Gilberg, E. Njamkepo, and I. Parent du Chatelet Evidence of Bordetella pertussis with persistent cough in a french area with very high whole-cell vaccine coverage J. Infect. Dis. 18 6 2002 415 418
13. Pertussis. United States, 1997-2000 MMWR 51 4 2002 73 77
14. R. Pebody The seroepidemiolgy of pertussis in Western Europe 2005 (In press)
15. C. Six, I. Bonmarin, S. Haeghebaert, E. Laurent, and S. Baron Épid́miologie de la coqueluche (1993-2000):: bilan de la surveillance hospitalìre et des investigations d'́pid́mies dans les collectivit́s en France Rev. Int. Pediatr. 36 2002 15 21
16. M.M. Jan, and S. Halperin Pertussis epidemic and sudden infant death syndrome Clin Pediatr 37 1998 449 451
17. S.D. Essery, M.W. Raza, and A. Zorgani The protective effect of immunisation against diphtheria, pertussis and tetanus (DPT) in relation to sudden infant death syndrome FEMS Immunol. Med. Microbiol. 25 1999 183 192
18. C. Lindgren, J. Milerad, and H. Lagercrantz Sudden infant death and prevalence of whooping cough in the Swedish and Norwegian communities Eur. J. Pediatr. 156 1997 405 409
19. A.T. Saadi, C.C. Blackwell, and S.D. Essery Developmental and environmental factors that enhance binding of Bordetella pertussis to human epithelial cells in relation to sudden infant death syndrome (SIDS) FEMS Immunol. Med. Microbiol. 16 1996 51 59
20. U. Heininger, K. Stehr, and G. Schmidt-Schlapfer Bordetella pertussis infections and sudden unexpected deaths in children Eur. J. Pediatr. 155 1996 551 553
21. E. Grimprel, P. B́gú, I. Anjak, E. Njamkepo, P. Fraņois, and N. Guiso Long term human serum antibody responses after immunization with whole-cell pertussis vaccine in France Clin. Diag. Lab. Immunol. 3 1996 93 97
22. N. Guiso, P. B́gú, and R. Cohen Comparison of pertussis antibody levels in children up to 5:years of age primed at 2, 3, 4:months and boostered in the second year of life with either DTPa or DTPw based combination vaccines in France. Toronto ICAAC 2000 (Abstract)
23. E. Grimprel, E. Njamkepo, P. B́gú, and N. Guiso Rapid diagnosis of pertussis in young infants: comparison of culture, PCR, and infant's and mother's serology Clin. Diag. Lab. Immunol. 4 1997 723 726
24. S.A. Halperin, R. Bortolussi, J.M. Langley, B. Miller, and B.J. Eastwood Seven days of erythromycin estolate is as effective as fourteen days for the treatment of Bordetella pertussis infections Pediatr. 100 1997 65 71
25. J.E. Hope State of the art in antibacterial suceptibility of Bordetella pertussis and antibiotic treatment of pertussis Infect. 26 1998 242 246
26. J.E. Hope Erythromycin Study Group Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis Pediatr. Infect. Dis. J. 11 1992 189 193
27. M.A. Honein, L.J. Paulozzi, and I.M. Himelright Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromycin: a case review and cohort study Lancet 353 1999 18 25
28. Anonyme Hypertrophic pyloric stenosis in infants following pertussis prophylaxis with erythromycin 1999 MMWR Knoxville, Tennesse 1117 1120
29. D. Torre, F. Maggiolo, and C. Sampietro Comparative clinical study of josamycin and erythromycin in pertussis Chemioterapia 3 1984 255 257
30. M.H. Lebel, and S. Mehra Efficacy and safety of clarithromycin versus erythromycin for the treatment of pertussis: a prospective, randomized, single blind trial Pediatr. Infect. Dis. J. 20 2001 1149 1154
31. M.E. Pichichero, W.J. Hoeger, and J.R. Casey Azithromycin for the treatment of pertussis Pediatr. Infect. Dis. J. 22 2003 847 849
32. J.E. Hope, U. Halm, and H.J. Hagedorn Comparison of erythromycin ethylsuccinate and cotrimoxazole for treatment of pertussis Infect. 17 1989 227 231
33. D.L. Miller, E.M. Ross, R. Alderslade, M.H. Bellman, and N.S. Rawson Pertussis immunisation and serious acute neurological illness in children BMJ 282 1981 1595 1599
34. W.D. Shields, C. Nielsen, and D. Buch Relationship of pertussis immunization to the onset of neurologic disorders: a retrospective epidemiologic study J. Pediatr. 113 1988 801 805
35. M.R. Griffin, W.A. Ray, E.A. Mortimer, G.M. Fenichel, and W. Schaffner Risk of seizures and encephalopathy after immunization with the diphtheria-tetanus-pertussis vaccine JAMA 263 12 1990 1641 1645
36. J.D. Cherry Pertussis vaccine encephalopathy: it is time to recognize it as the myth that it is JAMA 263 1990 1679 1680
37. P.C. B́gú, E. Grimprel, M.D. Giovannangeli, and V.I. Abitbol Comparative reactogenicity and immunogenicity of booster doses of diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine and diphtheria-tetanus-inactivated poliovirus vaccine in preadolescents Pediatr. Infect. Dis. J. 17 1998 804 809
38. J. Gaudelus, N. Guiso, and P. Reinert Les vaccins coquelucheux: composition, toĺrance, immunoǵnicit́ et efficacit́. Justification du calendrier vaccinal en France MMI 31 2001 86 97
39. D.M. Skowronski, V.P. Remple, and J. Macnabb Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact Pediatr. 112 2003 445 453
40. Calendrier vaccinal 1998 BEH 15 1998
41. Calendrier vaccinal 2003 BEH 6 2003
42. Directive 2000/54CE du Parlement européen et du Conseil du 18 septembre 2000 concernant la protection des travailleurs contre les risques liés à l'exposition à des agents biologiques au travail.
43. Calendrier vaccinal 2004. Avis du conseil suṕrieur d'hygìne publique de France, 19 mars 2004 BEH 28-29 2004 121 132
44. Arrêté du 3 mai 1989 relatif aux durées et conditions d'éviction et aux mesures de prophylaxie à l'égard des ́l̀ves et du personnel dans les établissements d'enseignement et d'éducation publics et privés en cas de maladie contagieuse. Journal Officiel du 31 mai 1989.
45. Guide de la conduite à tenir en cas de maladies transmissibles dans une collectivité d'enfants CSHPF du 14 mars 2003. Données consultables à l'URL:: http://www.sante.gouv.fr/index.html.
46. Guide des vaccinations 2003. Données consultables à l'URL:: http://www.sante.gouv.fr/index.html.
47. R.W. Stekele, S.G.F. Wassilak, and W.N. Adkins Evidence for a high attack rate and efficacy of erythtomycin prophylaxis in a pertussis outbreak in a facility for the developmentally disabled J. Infect. Dis. 157 3 1988 434 440
48. M.A. Sprauer, S.L. Cochi, and E.R. Zell Prevention of secondary transmission of pertussis in households with early use of erythromycin Am. J. Dis. Child. 146 1992 177 181
49. R.J. Biellik, P.A. Patriarca, and J.R. Mullen Risk factors for community -and household- acquired pertussis during a large scale outbreak in central Wisconsin J. Infect. Dis. 157 6 1988 1134 1141
50. G. De Serres, N. Boulianne, and B. Duval Field effectiveness of erythromycin prophylaxis to prevent pertussis within families Pediatr. Infect. Dis. J. 14 1995 969 974